Republic of the Philippines
Department of Health
**BUREAU OF FOOD AND DRUGS**
Filinvest Corporate City
Alabang, Muntinlupa City

Date: 12 October 2004

Bureau Circular
No. 14 s. 2004

**SUBJECT : Submission of adverse drug reaction reports on COX-2 inhibitors as part of safety monitoring.**

The Bureau of Food and Drugs, after careful evaluation on the recent voluntary withdrawal of **ROFECOXIB (VIOXX)** from the Philippine market by its local company Merck Sharp & Dohme Philippines, has determined that all concerned pharmaceutical establishments with COX-2 inhibitors are required to monitor and submit adverse drug reaction reports on serious cardiovascular events including heart attacks and strokes.

Accordingly, the following COX-2 inhibitors shall be monitored and establishments should submit a monthly adverse drug reactions reports for 3 years:

(1) Celecoxib
(2) Valdecoxib
(3) Meloxicam
(4) Etoricoxib

For strict and immediate compliance.

**(Sgd) Prof. LETICIA-BARBARA B. GUTIERREZ, M.S.**
Director